Display options
Cite
Stochino Loi E, Pontis A, Cofelice V, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. Int J Womens Health. 2019;11:443-449doi: 10.2147/IJWH.S204275.
Stochino Loi, E., Pontis, A., Cofelice, V., Pirarba, S., Fais, M. F., Daniilidis, A., Melis, I., Paoletti, A. M., & Angioni, S. (2019). Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. International journal of women's health, 11443-449. https://doi.org/10.2147/IJWH.S204275
Stochino Loi, Emanuela, et al. "Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study." International journal of women's health vol. 11 (2019): 443-449. doi: https://doi.org/10.2147/IJWH.S204275
Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, Melis I, Paoletti AM, Angioni S. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147/IJWH.S204275. eCollection 2019. PMID: 31496832; PMCID: PMC6697671.
Copy Download .nbib Format: NLM
Share it on

Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147/IJWH.S204275. eCollection 2019.

Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study.

International journal of women's health

Emanuela Stochino Loi, Alessandro Pontis, Vito Cofelice, Silvia Pirarba, Maria Francesca Fais, Angelos Daniilidis, Irene Melis, Anna Maria Paoletti, Stefano Angioni

Affiliations

  1. Division of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
  2. Division of Gynecology and Obstetric, Hospital San Francesco, Nuoro, Italy.
  3. 2nd University Department of Obstetrics and Gynecology, Hippokratio General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

PMID: 31496832 PMCID: PMC6697671 DOI: 10.2147/IJWH.S204275

Abstract

PURPOSE: The aim of the present study was to evaluate the effectiveness of the ultramicronized-palmitoylethanolamide (um-PEA) and co-micronised palmitoylethanolamide/polydatin m(PEA/PLD) in the management of chronic pelvic pain related to endometriosis in patients desiring pregnancy.

PATIENTS AND METHODS: Thirty symptomatic women with laparoscopic diagnosis of endometriosis and pregnancy desire were enrolled. Patients were treated with um-PEA twice daily for 10 days followed by m(PEA/PLD) twice daily for 80 days. Intensity of chronic pelvic pain, dyspareunia, dysmenorrhea, dyschezia, and dysuria were evaluated at baseline, after 10, 30, 60, 90 days and after 30 days from the end of treatment, by VAS. Quality of life and women's psychological well-being were evaluated at baseline and at the end of the treatment after 90 days with 36-Item Short Form Health Survey questionnaire and Symptom Check list-90 questionnaire, respectively. All collected data were analyzed with the non-parametric Wilcoxon test.

RESULTS: At the end of the treatment, all patients showed a significant improvement in chronic pelvic pain, deep dyspareunia, dysmenorrhea, dyschezia, as well as in quality of life and psychological well-being.

CONCLUSION: In spite of the study's limited sample size and the open-label design, this research suggests the efficacy of um-PEA and m(PEA/PLD) in reducing painful symptomatology and improving quality of life as well as psychological well-being in patients suffering from endometriosis. Additionally, this treatment did not show any serious side effect, proving particularly suitable for women with pregnancy desire and without other infertility factors.

Keywords: chronic pelvic pain; co-micronized palmitoylethanolamide and polydatin; endometriosis; psychological well-being; quality of life; ultramicronized-palmitoylethanolamide

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Int J Tissue React. 1999;21(4):93-104 - PubMed
  2. Fertil Steril. 2002 Oct;78(4):782-6 - PubMed
  3. Am J Reprod Immunol. 2004 Oct;52(4):267-75 - PubMed
  4. Hum Reprod Update. 1996 Sep-Oct;2(5):385-98 - PubMed
  5. Hum Reprod. 2005 Jul;20(7):2014-20 - PubMed
  6. Hum Reprod. 2006 Jun;21(6):1629-34 - PubMed
  7. Fertil Steril. 2006 Nov;86(5):1336-43 - PubMed
  8. Vet Immunol Immunopathol. 2010 Jan 15;133(1):9-15 - PubMed
  9. Biochimie. 2010 Jun;92(6):724-7 - PubMed
  10. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):76-9 - PubMed
  11. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6 - PubMed
  12. J Neuroinflammation. 2011 Aug 10;8:94 - PubMed
  13. Int J Gynaecol Obstet. 2012 Jan;116(1):57-60 - PubMed
  14. Expert Opin Ther Targets. 2012 Mar;16(3):237-41 - PubMed
  15. Bull Exp Biol Med. 2011 Nov;152(1):93-7 - PubMed
  16. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3312-25 - PubMed
  17. JAMA Psychiatry. 2013 Feb;70(2):176-84 - PubMed
  18. J Pharmacol Sci. 2013;121(2):89-94 - PubMed
  19. CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):34-44 - PubMed
  20. Acta Neuropathol. 2013 May;125(5):637-50 - PubMed
  21. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):209-13 - PubMed
  22. Reprod Biol Endocrinol. 2013 Sep 26;11:94 - PubMed
  23. Inflammopharmacology. 2014 Apr;22(2):79-94 - PubMed
  24. Gynecol Endocrinol. 2014 Jul;30(7):472-7 - PubMed
  25. J Neuroinflammation. 2014 Aug 28;11:136 - PubMed
  26. Hum Reprod Update. 2015 Jan-Feb;21(1):136-52 - PubMed
  27. Gynecol Endocrinol. 2015 May;31(5):406-8 - PubMed
  28. Pain. 2016 Jan;157(1):80-91 - PubMed
  29. Gynecol Endocrinol. 2015;31(8):595-8 - PubMed
  30. Gynecol Endocrinol. 2015 Jun;31(6):454-7 - PubMed
  31. Front Pharmacol. 2016 Oct 14;7:382 - PubMed
  32. Arch Gynecol Obstet. 2017 Apr;295(4):827-832 - PubMed
  33. Neurosci Biobehav Rev. 2017 Aug;79:119-133 - PubMed
  34. Minerva Ginecol. 2017 Oct;69(5):438-439 - PubMed
  35. Front Pharmacol. 2018 Mar 20;9:249 - PubMed
  36. Pain. 1983 Sep;17(1):45-56 - PubMed
  37. Health Econ. 1993 Oct;2(3):217-27 - PubMed
  38. J Clin Epidemiol. 1998 Nov;51(11):1025-36 - PubMed

Publication Types